Clinical trial · Interventional
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia
NCT00358644CI-TRIAL-00010364completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Decitabine | Drug | Decitabine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Decitabine
Primary outcomes (1)
- measure
- Complete Response = Morphologic Complete Remission (mCR)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment. 2. Ineligible to receive intensive chemotherapy for their disease. 3. Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities. Exclusion Criteria: 1. Received previous treatment for AML. 2. Previously received Vidaza. 3. Received any other investigational agents within 30 days of first dose of study drug. 4. Uncontrolled intercurrent illness. 5. Had radiotherapy within 14 days prior to study enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.